The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1LCVB4     propan-2-yl7-[(1R,2S,3R,5S)- 3,5-dihydroxy...

Synonyms: SureCN1951740, CTK8E7258, 157283-68-6
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01964


High impact information on D01964


Chemical compound and disease context of D01964


Biological context of D01964

  • Few studies have been performed with brimonidine, travoprost, and bimatoprost, and it is suggested that more attention should be given to studies with these agents, as about 30% of patients with open angles and glaucomatous visual field defects have normal-tension glaucoma [13].
  • The mean IOPs in the supine position throughout the first and the second 24-h period of the week 2 visit as well as for the 48-h visit were statistically lower (p < 0.05) for the travoprost group [14].
  • RESULTS: Travoprost and bimatoprost did not cause significant reductions in systolic blood pressure during exercise and recovery [15].

Anatomical context of D01964


Associations of D01964 with other chemical compounds


Gene context of D01964

  • All FP (e.g. travoprost acid, fluprostenol), IP (iloprost) and TP (SQ29548) receptor-specific ligands exhibited low affinity (Ki > or = 1 microM) [23].
  • In conclusion, travoprost acid has the highest affinity, the highest FP-receptor-selectivity, and the highest potency at the FP receptor as compared to the other ocular hypotensive PG analogs known so far, including free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester [24].
  • CONCLUSIONS: Flu-like symptoms (abdominal cramps, malaise and URI) were reported in 4% of patients participating in clinical trials of travoprost but seldom reported postmarketing [25].
  • RESULTS: Mean IOP ranged from 16.2 to 17.4 mm Hg with the combination travoprost/timolol compared with 15.4 to 16.8 mm Hg in the concomitant travoprost + timolol group, from baselines of 23.1 to 25.6 mm Hg and 22.9 to 25.0 mm Hg, respectively [26].

Analytical, diagnostic and therapeutic context of D01964


  1. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Guenoun, J.M., Baudouin, C., Rat, P., Pauly, A., Warnet, J.M., Brignole-Baudouin, F. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  2. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Fellman, R.L., Sullivan, E.K., Ratliff, M., Silver, L.H., Whitson, J.T., Turner, F.D., Weiner, A.L., Davis, A.A. Ophthalmology (2002) [Pubmed]
  3. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Cantor, L.B., WuDunn, D., Cortes, A., Hoop, J., Knotts, S. Survey of ophthalmology. (2004) [Pubmed]
  4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Franks, W.A., Renard, J.P., Cunliffe, I.A., Rojanapongpun, P. Clinical therapeutics. (2006) [Pubmed]
  5. Acute anterior uveitis and corneal edema associated with travoprost. Faulkner, W.J., Burk, S.E. Arch. Ophthalmol. (2003) [Pubmed]
  6. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Thieme, H., Schimmat, C., Münzer, G., Boxberger, M., Fromm, M., Pfeiffer, N., Rosenthal, R. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  7. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Sharif, N.A., Kelly, C.R., Crider, J.Y. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  8. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis, R., Queiroz, C.F., Santos, L.C., Avila, M.P., Magacho, L. Clinical therapeutics. (2006) [Pubmed]
  9. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Flowers, B., Wand, M., Piltz-Seymour, J., Berke, S.J., Day, D., Teague, J., Smoot, T.M., Landry, T.A., Bergamini, M.V., Mallick, S. Clinical therapeutics (2006) [Pubmed]
  10. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with openangle glaucoma or ocular hypertension. Franks, W. Current medical research and opinion. (2006) [Pubmed]
  11. Prostaglandin analog treatment of glaucoma and ocular hypertension. Alexander, C.L., Miller, S.J., Abel, S.R. The Annals of pharmacotherapy. (2002) [Pubmed]
  12. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Suzuki, E.R., Meirelles Franklin, L., da Silva, L.J., Figueiredo, C.R., Agostini Netto, J., Batista, W.D. Current medical research and opinion. (2006) [Pubmed]
  13. Medical treatment of normal tension glaucoma. Hoyng, P.F., Kitazawa, Y. Survey of ophthalmology. (2002) [Pubmed]
  14. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. García-Feijoo, J., Martínez-de-la-Casa, J.M., Castillo, A., Méndez, C., Fernández-Vidal, A., García-Sánchez, J. Current medical research and opinion. (2006) [Pubmed]
  15. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. Inan, U.U., Ermis, S.S., Orman, A., Onrat, E., Yucel, A., Ozturk, F., Asagidag, A., Celik, A. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2004) [Pubmed]
  16. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arcieri, E.S., Santana, A., Rocha, F.N., Guapo, G.L., Costa, V.P. Arch. Ophthalmol. (2005) [Pubmed]
  17. Effects of travoprost on aqueous humor dynamics in monkeys. Toris, C.B., Zhan, G.L., Camras, C.B., McLaughlin, M.A. Journal of glaucoma. (2005) [Pubmed]
  18. Absence of vasoactive properties of travoprost in isolated porcine ciliary arteries. Allemann, R., Flammer, J., Haefliger, I.O. Klinische Monatsblätter für Augenheilkunde. (2003) [Pubmed]
  19. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Yee, R.W. Advances in therapy. (2006) [Pubmed]
  20. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. Kelly, C.R., Williams, G.W., Sharif, N.A. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  21. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Hellberg, M.R., McLaughlin, M.A., Sharif, N.A., DeSantis, L., Dean, T.R., Kyba, E.P., Bishop, J.E., Klimko, P.G., Zinke, P.W., Selliah, R.D., Barnes, G., DeFaller, J., Kothe, A., Landry, T., Sullivan, E.K., Andrew, R., Davis, A.A., Silver, L., Bergamini, M.V., Robertson, S., Weiner, A.L., Sallee, V.L. Survey of ophthalmology. (2002) [Pubmed]
  22. Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. Vetrugno, M., Sisto, D., Trabucco, T., Balducci, F., Delle Noci, N., Sborgia, C. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2005) [Pubmed]
  23. Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. Sharif, N.A., Davis, T.L. J. Pharm. Pharmacol. (2002) [Pubmed]
  24. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. Sharif, N.A., Kelly, C.R., Crider, J.Y., Williams, G.W., Xu, S.X. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2003) [Pubmed]
  25. Abdominal cramp as an adverse effect of travoprost. Lee, Y.C. Am. J. Ophthalmol. (2005) [Pubmed]
  26. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Schuman, J.S., Katz, G.J., Lewis, R.A., Henry, J.C., Mallick, S., Wells, D.T., Sullivan, E.K., Landry, T.A., Bergamini, M.V., Robertson, S.M. Am. J. Ophthalmol. (2005) [Pubmed]
  27. Travoprost. Waugh, J., Jarvis, B. Drugs & aging. (2002) [Pubmed]
  28. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Holmstrom, S., Buchholz, P., Walt, J., Wickstrøm, J., Aagren, M. Current medical research and opinion. (2005) [Pubmed]
  29. The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery. Arici, M.K., Erdogan, H., Toker, I., Vural, A., Topalkara, A. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2006) [Pubmed]
  30. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. McCue, B.A., Cason, M.M., Curtis, M.A., Faulkner, R.D., Dahlin, D.C. Journal of pharmaceutical and biomedical analysis. (2002) [Pubmed]
WikiGenes - Universities